GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Purchases of Investments
Cash used to buy marketable securities and other investments.
GRAIL, Inc.NASDAQ: GRAL
Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026
Purchases of investments growth accelerates
Q2 FY2026 purchases of investments of $462.44M (cash outflow) rose 64.0% year over year, ahead of the -40.7% change in trailing-twelve-month purchases of investments. Sequentially, it rose 36.9% from the prior quarter.
Context
- Purchases of investments amounted to 889.0% of revenue in FY2025, up 454.4 pp from a year earlier.
- Purchases of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +64.0% holds above the trailing-twelve-month pace of -40.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (1.31B) USD
- Year-over-year change
- -139.7%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.31B) | -139.7% |
| FY2024 | 2024-12-31 | (545.8M) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Purchases of Investments vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's LTM Jun 2026 purchases of investments of $297.79M is the 2nd largest of the 10 companies compared; the peer median is $53.97M.
- Its year-over-year change of -40.7% is the 6th highest of 7, against a peer median of +18.4%.
- Purchases of investments amounts to 180.2% of revenue for GRAL, versus a peer median of 11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.07B | +7529.8% | +36.2% | 83.5% | |
| LTM Jun 2026 | $297.79M | -40.7% | — | 180.2% | |
| LTM Mar 2026 | $212.93M | +35.7% | +20.0% | 330.1% | |
| LTM Mar 2026 | $195.42M | +1.0% | +11.9% | 57.5% | |
| LTM Mar 2026 | $90.85M | -67.2% | -42.8% | 28.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $53.97M | -20.3% | — | 11.9% |
| LTM Jun 2026 | $500K | — | -82.8% | 0.1% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GRAL) | $53.97M | +18.4% | +11.9% | 11.9% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.25B) | (5.4B) | (1.47B) | (2.03B) | (408.35M) |
| Depreciation & Amortization | 58.45M | 154.76M | 158.7M | 158.06M | 156.34M |
| Deferred Income Tax | 0 | (39.06M) | (38.15M) | (134.25M) | (126.15M) |
| Stock-Based Compensation | 681.91M | 75.73M | 97.24M | 86.08M | 58.28M |
| Change in Working Capital | 21.59M | (14.46M) | 7.72M | (24.28M) | 12.41M |
| Accounts Receivables | (6.88M) | (8.68M) | (1.38M) | (3.37M) | 1.69M |
| Inventory | (5.67M) | (14.08M) | (1.94M) | 3.07M | 2.62M |
| Accounts Payables | 1.3M | 2.34M | 2.89M | (14.64M) | (2.73M) |
| Other Working Capital | 32.85M | 5.95M | 8.16M | (9.35M) | 10.84M |
| Other Non-Cash Items | (201M) | 4.66B | 644.39M | 1.36B | 8.46M |
| Operating Cash Flow | (688.13M) | (561.31M) | (595.8M) | (577.16M) | (299.01M) |
| Capital Expenditures | (69.93M) | (22.86M) | (12.89M) | (5.21M) | (909K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (545.8M) | (1.31B) |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.22B |
| Other Investing Activities | 414.74M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 344.81M | (22.86M) | (12.89M) | (551.01M) | (85.05M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.98M | 0 | 0 | 0 | 423.32M |
| Common Stock Repurchased | (170K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 388.93M | 604.82M | 463.77M | 1.24B | 0 |
| Financing Cash Flow | 394.74M | 604.82M | 463.77M | 1.24B | 423.32M |
| Effect of Forex Changes | (194.61M) | (511K) | 305K | (62K) | (147K) |
| Net Change in Cash | (143.19M) | 20.13M | (144.62M) | 116.07M | 39.12M |
| Free Cash Flow | (758.06M) | (584.17M) | (608.69M) | (582.36M) | (299.01M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.